Mar, 2005

U.S.A.
News / Therapeutic Area News
Fujisawa Healthcare, Inc. and Roche Announce Co-promotion of MYCAMINE™
Fujisawa Healthcare, Inc. and Roche Pharmaceuticals today announced a partnership for the U.S. co-promotion of MYCAMINE™ (micafungin sodium) injection, Fujisawa's newly approved product for the...
Read More
U.S.A.
News / Therapeutic Area News
OSI Pharmaceuticals Announces Tarceva Granted First European Approval in Switzerland; First and Only Agent Approved in its Class to Show a Survival Benefit
MELVILLE, N.Y.--(BUSINESS WIRE)--March 22, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Swiss health authority, Swissmedic, has approved Tarceva™ (erlotinib) for the...
Read More
U.S.A.
News / Therapeutic Area News
Mycamine™ Receives FDA Approval
Fujisawa Healthcare, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the use of micafungin sodium, the antifungal product for prophylaxis of Candida infections...
Read More

Jan, 2005

U.S.A.
News / Therapeutic Area News
Data from Phase III Study Show Tarceva Plus Gemcitabine Significantly Improves Survival Compared to Gemcitabine Alone in Advanced Pancreatic Cancer Patients
HOLLYWOOD, Fla.--(BUSINESS WIRE)--Jan. 27, 2005--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), Genentech, Inc. (NYSE: DNA), and Roche (SWX Zurich) announced today that a randomized Phase III clinical...
Read More